US Stock Market Movement: AstraZeneca surged on October 30 as Q3 performance exceeded expectations, $1.5 billion in cost reductions, and growth in oncology

AstraZeneca Surged on October 30: Analysis

Key points: Q3 performance exceeded expectations, $1.5 billion in cost reduction, oncology growth

1. On October 30, the company released its Q3 2026 results: total revenue of $16.209 billion, up 7% year-on-year; core EPS of $2.79, up 17% and up 19% at constant exchange rates; post-tax profit of $3.12 billion, up 23%. Oncology revenue reached $7.77 billion, up 17% and accounting for 48% of the total; Tagrisso at $2.09 billion and Imfinzi at $1.99 billion both exceeded institutional expectations.

2. On October 30, the company announced its "Reshaping for Sustainable Growth" plan, aiming to save $1.5 billion annually, with a one-off restructuring cost of up to $2.0 billion, to be largely completed by the end of 2029. The savings will mainly be reinvested into more than 180 pipeline projects. The company reaffirmed its guidance of mid to high single-digit growth in revenue and low double-digit growth in core EPS by 2026.

3. On October 30, the company disclosed that it expects to deliver potential peak annual revenue of over $20.0 billion by 2027 and maintained its $80.0 billion revenue target for 2030. In October, it completed a $2.0 billion equity investment in Summit Therapeutics, acquiring around 12.0% of its common shares. On October 29, Enhertu won the 2026 International Prix Galien Award for Best Biotechnology Product.

(Disclaimer: This content is generated by AI technology from publicly available information and is for reference only. It does not constitute investment advice.)